Company intelligence / Profile preview
Techfields Pharma
Suzhou, Jiangsu Sheng, Chinaprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Lead candidate X0002 is in Phase 3 clinical trials under a special protocol assessment and Fast Track designation for osteoarthritis pain. Early studies have shown X0002 has potential to achieve 100X greater tissue level of Ibuprofen compared to oral administration.
- Therapeutic areas
- PsychiatryMen's HealthRheumatologyDermatologyNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Techfields Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Techfields Pharma.